ImmunoGen, Inc. - Common Stock (NQ:IMGN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunoGen, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Immunogen's Earnings: A Preview ↗

April 27, 2023

Via Benzinga

ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer

April 24, 2023

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results

April 13, 2023

From ImmunoGen Inc.

Via Business Wire

Could This Move Make Vertex's Next Blockbuster Even Bigger? ↗

April 12, 2023

Vertex is showing it can branch out beyond its cystic fibrosis specialty.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

April 07, 2023

Via Benzinga

Earnings Scheduled For March 1, 2023 ↗

March 01, 2023

Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.

Via Benzinga

Analyst Ratings for Immunogen ↗

January 23, 2023

Via Benzinga

Analyst Ratings for Immunogen ↗

December 30, 2022

Via Benzinga

ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors

April 06, 2023

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 03, 2023

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting

March 25, 2023

From ImmunoGen, Inc.

Via Business Wire

6 Analysts Have This to Say About Immunogen ↗

December 30, 2022

Via Benzinga

What 6 Analyst Ratings Have To Say About Immunogen ↗

December 30, 2022

Via Benzinga

Why Shares of MacroGenics Jumped Thursday ↗

March 09, 2023

The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy.

Via The Motley Fool

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 01, 2023

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Allows Vertex Pharma Use Its Technology For Conditioning Agents For Use With Gene Editing ↗

March 01, 2023

Via Benzinga

ImmunoGen Reports Recent Progress and 2022 Financial Results

March 01, 2023

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents

March 01, 2023

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

February 22, 2023

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results

February 15, 2023

From ImmunoGen Inc.

Via Business Wire

ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

February 01, 2023

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 04, 2023

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs

January 04, 2023

From ImmunoGen, Inc.

Via Business Wire

What You Missed On Wall Street On Friday ↗

December 31, 2022

In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold.

Via Talk Markets

Futu Holdings, UP Fintech Holding And Some Other Big Stocks Moving Lower On Friday ↗

December 30, 2022

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Friday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Ardelyx To Rally 160%? Here Are 10 Other Price Target Changes For Friday ↗

December 30, 2022

Citigroup raised Ardelyx, Inc. (NASDAQ: ARDX) price target from $6 to $7. Citigroup analyst Yigal Nochomovitz maintained a Buy rating on the stock. Ardelyx shares rose 9.4% to $2.7685 on Friday.

Via Benzinga

ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed

December 28, 2022

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen's Newly Approved Ovarian Cancer Drug Listed As Preferred Regime ↗

December 28, 2022

The National Comprehensive Cancer Network (NCCN) released new guidelines for ovarian cancer treatment, which include ImmunoGen Inc's (NASDAQ: IMGN) Elahere (mirvetuximab soravtansine-gynx) as a...

Via Benzinga

ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference

December 27, 2022

From ImmunoGen, Inc.

Via Business Wire

Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific ↗

December 17, 2022

Boston Scientific will pay $523 million for a 65% stake in Acotec Scientific, a Beijing medical device company. Boston Scientific said the acquisition will build up its presence in China, and it will...

Via Talk Markets

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.